CytoDyn (STU:296) Total Equity: €-88.23 Mil (As of Feb. 2026)


STU:296 CytoDyn Inc STU:296
28 GF Score
Price €0.20
! 1 Warning Sign
View Full Analysis

What is CytoDyn Total Equity?

CytoDyn STU:296 +3.13% 28 Total Equity is €-88.23 Mil as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

CytoDyn's total equity for the quarter that ended in Feb. 2026 was €-88.23 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

CytoDyn Total Equity Historical Data

* Premium members only.

The historical data trend for CytoDyn's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Total Equity Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.30 -89.30 -100.74 -108.00 -85.19

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.26 -85.19 -85.48 -103.58 -88.23
STU:296
28GF Score
CytoDyn Inc STU:296
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

CytoDyn's Total Equity for the fiscal year that ended in May. 2025 is calculated as

Total Equity=Total Assets(Q: May. 2025 )-Total Liabilities(Q: May. 2025 )
=16.008-101.197
=-85.19

CytoDyn's Total Equity for the quarter that ended in Feb. 2026 is calculated as

Total Equity=Total Assets(Q: Feb. 2026 )-Total Liabilities(Q: Feb. 2026 )
=15.648-103.875
=-88.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €-88.23 Mil mean?
CytoDyn (STU:296) has a Total Equity of €-88.23 Mil as of Feb. 2026. The total amount of equity as record on a company's balance sheet. View historical data for CytoDyn and its competitors.
Is CytoDyn's Total Equity too high?
CytoDyn's current Total Equity is €-88.23 Mil. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Total Equity compare to VSTM and IRD?
CytoDyn's Total Equity of €-88.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for CytoDyn and its competitors. CytoDyn's current Total Equity is €-88.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Total Equity of €-88.23 Mil. The current Total Equity is €-88.23 Mil. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For CytoDyn (STU:296), the current Total Equity is €-88.23 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for STU:296

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price